Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, Briantais M J, Buffet C, Soussi T
Service des Maladies du Foie et de l'Appareil Digestif, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Gut. 1995 Mar;36(3):455-8. doi: 10.1136/gut.36.3.455.
Specific markers for pancreatic or biliary cancer have been developed in the past few years. Ca 19-9 has a good sensitivity but it is also increased in benign cholestasis. Mutations in the p53 gene are commonly reported in pancreatic cancer and can be detected by a serological analysis. The aim of this work was to find out the sensitivity and specificity of this new assay in diagnosing cancer of the pancreas or of the bile ducts. The presence of antibodies against p53 was determined by an enzyme linked immunosorbent assay (ELISA) in 29 patients with pancreatic cancer, 33 with biliary tract cancer, and 33 with benign biliary or pancreatic diseases as controls. p53 Antibodies were detected in eight of 29 patients with pancreatic cancer (28%), in five of 33 patients with biliary tract (15%), and in one patient (3%) with stones of the common bile duct. The sensitivity and the specificity for the diagnosis of malignant biliary or pancreatic diseases were 21% and 96% respectively. It is concluded that the presence of p53 antibodies in the serum of patients with pancreatic and biliary diseases is specific for malignancy and independent from the presence of cholestatic disease.
在过去几年中，已经开发出了胰腺癌或胆管癌的特异性标志物。糖类抗原19-9（Ca 19-9）具有良好的敏感性，但在良性胆汁淤积时也会升高。p53基因的突变在胰腺癌中普遍存在，并且可以通过血清学分析检测到。这项工作的目的是找出这种新检测方法在诊断胰腺癌或胆管癌中的敏感性和特异性。采用酶联免疫吸附测定（ELISA）法检测了29例胰腺癌患者、33例胆管癌患者以及33例患有良性胆管或胰腺疾病的对照者血清中抗p53抗体的存在情况。在29例胰腺癌患者中有8例（28%）检测到p53抗体，33例胆管癌患者中有5例（15%）检测到，在1例胆总管结石患者中检测到（3%）。诊断恶性胆管或胰腺疾病的敏感性和特异性分别为21%和96%。得出的结论是，胰腺和胆管疾病患者血清中p53抗体的存在对恶性肿瘤具有特异性，且与胆汁淤积性疾病的存在无关。
